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Human NAD(P)H:quinone oxidoreductase type I (hNQO1)
activation of quinone propionic acid trigger groups†
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Maria F. Mendoza, Nicole M. Hollabaugh, Suraj U. Hettiarachchi, and Robin L. McCarley*
Department of Chemistry, Louisiana State University, 232 Choppin Hall, Baton Rouge, LA
70803-1804

Abstract
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NAD(P)H:quinone oxidoreductase type I (NQO1) is a target enzyme for triggered delivery of
drugs at inflamed tissue and tumor sites, particularly those that challenge traditional therapies.
Prodrugs, macromolecules, and molecular assemblies possessing trigger groups that can be
cleaved by environmental stimuli are vehicles with the potential to yield active drug only at
prescribed sites. Furthermore, quinone propionic acids (QPAs) covalently attached to prodrugs or
liposome surfaces can be removed by application of a reductive trigger stimulus, such as that from
NQO1; their rates of reductive activation should be tunable via QPA structure. We explored in
detail the recombinant human NAD(P)H:quinone oxidoreductase type I (rhNQO1)-catalyzed
NADH reduction of a family of substituted QPAs and obtained high precision kinetic parameters.
It is found that small changes in QPA structure—in particular, single atom and function group
substitutions on the quinone ring at R1—lead to significant impacts on the Michaelis constant
(Km), maximum velocity (Vmax), catalytic constant (kcat), and catalytic efficiency (kcat/Km).
Molecular docking simulations demonstrate that alterations in QPA structure result in large
changes in QPA alignment and placement with respect to the flavin isoalloxazine ring in the active
site of rhNQO1; a qualitative relationship exists between the kinetic parameters and the depth of
QPA penetration into the rhNQO1 active site. From a quantitative perspective, a very good
correlation is observed between log(kcat/Km) and the molecular-docking-derived distance between
flavin hydride donor site and quinone hydride acceptor site in the QPAs, an observation that is in
agreement with developing theories. The comprehensive kinetic and molecular modeling
knowledge obtained for the interaction of recombinant human NQO1 with the quinone propionic
acid analogues provides insight into the design and implementation of the QPA trigger groups for
drug delivery applications.

$watermark-text

In the past two decades, there has been remarkable interest in the activation of drug delivery
systems and cellular processes by enzymes associated with inflammatory diseases and
cancer.1 Such avenues have been addressed in two ways: 1) through the use of such
endogenous, upregulated proteins to selectively activate antitumor compounds,2
prodrugs,3–6 and very recently liposomes;7–13 and 2) targeting these enzymes with
molecules that deactivate them, thereby causing cell death through accumulation of
damaging species, such as superoxide.14 Among the enzymes used as stimuli for these
potential therapeutic routes, a significant research effort has been directed at a subgroup of
reductase enzymes, of which NAD(P)H:quinone oxidoreductase-1 (NQO1, DT-diaphorase,
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(CHE-0910845).
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EC 1.6.99.2)15, 16 has become of great interest.17 This homodimeric flavoprotein is unique
among reductases, as it catalyzes the direct two-electron reduction of a wide variety
quinones using NADH or NADPH as cofactor.15, 18 NQO1 is located mainly in the cytosol
of cells, but can be found also in the nucleus, endoplasmic reticulum, cellular membrane,
and mitochondria, as well as extracellularly.15, 19–25 The overexpression of human NQO1 in
certain cancer tumor tissues (e.g. non-small cell lung, pancreas, and colon)26–30 makes it a
valuable target for activating stimuli-responsive drug delivery systems based on quinone
derivatives, such as prodrugs31 and liposomes.32 As a result, many groups have been
actively studying the molecular structure of NQO1 using crystallographic methods so as to
improve knowledge regarding its native structure (Protein Data Bank (PDB) accession code
1D4A),33 as well as its behavior with substrates, such as duroquinone (PDB accession code
1DXO), or inhibitors, including dicoumarol (PDB accession code 2F1O).33–38 Importantly,
the ability of NQO1 to reductively activate sophisticated quinone and quinoidal compounds
makes it an ideal target for the development of antitumor compounds39, 40 and
prodrugs.31, 41 However, the quantitative behavior of human NQO1 with structurally
similar, simple quinones, or quinones that can be used as trigger groups for prodrugs and
delivery vehicles, has to date not been assessed.

$watermark-text

Trigger groups that can be activated by a reductive stimulus, and as a result subsequently
undergo cleavage from a targeted group,6 hold much promise in the development of
endogenously-triggered prodrugs and drug delivery vehicles, such as liposomes, as well as
imaging strategies based on prodyes.42, 43 Our group has shown that reductively-activated
liposomes can have their contents delivered upon self-cleavage of the reduced quinone
propionic acid headgroup of the fusogenic lipids composing the liposomes; similarly, such
cleavage of the reduced quinone from cloaked probes (prodyes) results in fluorescent
signaling of human NQO1 activity.32, 42 Variants of the quinone propionic acid (QPA)
trigger group have also been investigated for prodrugs, such as those based on mustard44
and oxindoles.45

$watermark-text

The key step for these applications is the initial reduction process of the cleavable quinone
head group that is attached to the target molecule (lipid, drug, dye), a process that should be
controlled by the structure of the trimethyl-locked (Thorpe-Ingold or gem-disubstituent
effect)46–48 quinone propionic acid trigger, Scheme 1. The trimethyl-lock effect comes
about when R3=R4=CH3, and it leads to a more rapid cyclization of the hydroquinone to
yield at higher rates the lactone and the released target molecule, R’H, Scheme 1.32
Tunability in the reductive triggering of QPA groups for either prodrug or liposome delivery
applications should be possible as a result of substituent variation at R1, R2, and R3.
Although there exists a good number of reports on structure-relationship activity49–56 and
docking studies of NQO1 inhibitors and substrates for anticancer therapy,14, 35, 57–62 there is
only one published report that provides Michaelis constant (Km) and maximum velocity
(Vmax) values for the interaction of human NAD(P)H:quinone oxidoreductase-1 with a
simple quinone.44 In addition, the significant differences in reactivity of human NQO1 and
rat NQO1 with specific quinone species63–65 suggest limited applicability of structurereactivity relationship predictions based on rat NQO1.66–68
In this report, we examine a family of substituted quinone propionic acid (QPA) derivatives
as potential substrates for recombinant human NQO1. We report on detailed solution-phase
rhNQO1 kinetic parameters, namely the Michaelis constant (Km), maximum velocity
(Vmax), catalytic constant (kcat), and catalytic efficiency (kcat/Km). Using the known crystal
structure of the hNQO1-duroquinone complex (1DXO),33 six different molecular docking
receptors were delineated (changing interface radius, oxidation state of cofactor, and active
site definition). Quinone derivatives were docked in each receptor to determine if there were
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any differences in the outcomes and to have a better prediction for the orientation of quinone
propionic acids in the active site of rhNQO1. Furthermore, we explored possible correlations
between the experimental observables extracted from the kinetic assays and those obtained
from the docking studies.

MATERIALS AND METHODS
Materials

$watermark-text

Recombinant human enzyme NAD(P)H:quinone oxidoreductase-1 (EC 1.6.99.2) (rhNQO1),
nicotinamide adenine dinucleotide reduced (β-NADH), and bovine serum albumin (BSA)
were purchased from Sigma (D1315, N8129, A3294). Potassium dihydrogen phosphate
(KH2PO4, Fluka 60219), dipotassium hydrogen phosphate (K2HPO4, Fisher P288),
potassium chloride (KCl, Sigma P9541) and potassium hydroxide pellets (KOH,
Mallinckrodt) were used to make the buffer. Ethyl alcohol (200 Proof) was purchased from
Pharmaco-AAPER. High-purity water was obtained from a Nanopure Diamond Barnstead
System (18.2 MΩ-cm). The quinone propionic acid substrates were synthesized as
previously described69 or in the Supporting Information. The quartz 96-well microplate used
in the enzyme assays was purchased from Hellma (730.009-QG). A FLUOstar Optima plate
reader from BMG Labtech was used to follow NADH consumption during the enzyme
assay.
Enzyme Kinetic Assay

$watermark-text
$watermark-text

Enzyme kinetic parameters were determined using UV-visible spectroscopy by adapting a
previous assay70 to a well plate reader and 96-well quartz plate. The oxidation of NADH at
340 nm was measured using an experimentally determined extinction coefficient of 4390
M−1cm−1 (see Supporting Information). Kinetic experiments were performed on three
different days with at least three replicates of each condition performed. The assay solution
consisted of 0.1 M phosphate buffer/0.1 M KCl solution at pH 7.10 containing 0.007% of
bovine serum albumin, 100 µL of appropriate concentration of quinone substrate, 50 µL of a
400 µM NADH solution, and 50 µL of enzyme solution (0.11–3.00 µg). The total assay
volume was 200 µL. All stock quinone solutions were prepared by dissolving each quinone
in ethanol (100 µL) with subsequent dilution to 10.00±0.02 mL with 0.007% BSA solution.
Quinone solutions of the desired concentrations were made by taking the appropriate
volume from the quinone stock solution and diluting it to 10.00±0.02 mL in a volumetric
flask. The solutions were kept in the dark at room temperature (22±2 °C), for approximately
2 h before the experiments were started. Once the 96-well plate was filled with the assay
solutions, except the NADH solution, it was placed into the instrument and left to sit for 5
min before starting the measurements. The enzyme reaction was initiated by automated
dispensing of the NADH solution into the wells, and the absorbance change at 340 nm was
measured for 1.6 min at room temperature (22 to 26 °C). The linear portion of the
absorbance vs. time graphs (the first 20 seconds to 1 min) were fitted, and the slopes were
calculated (velocity). The average velocity (slope) from the replicates was used to calculate
the kinetic parameters, with the Q–test being applied so as to reject values outside of the
90% confidence level.71 Plots of average velocity versus quinone concentration were used to
obtain apparent Km and Vmax values from non-linear least squares analysis using algorithms
developed by Cleveland for Michaelis-Menten kinetics.72 In some cases, the t-test was
applied to kinetic parameter values for different substrates so as to determine if they were
statistically different at the 95% confidence level.73 Attempts to obtain the kinetic
parameters for quinone propionic acids with R1 substituents of N-methylamine (QMe-NCOOH) and N-(n-propyl)amine (Qn-pr-NH-COOH) were met with frustration, because the
results obtained are not reliable due to both substrates absorbing light at the wavelength (340
nm) that NADH consumption is measured.
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Docking

$watermark-text

Docking studies were performed using FlexX from LeadIT (1.3.0 version).74–81 Quinone
structures were prepared in Chemdraw3D and subsequently minimized using Sybyl-X
(Version 1.1.1) using the Tripos force field for suitable bond distances and angles, and the
Gasteiger-Hückel method for charge calculation; the minimized quinone structures were
used without modification in the docking studies. Enzyme coordinates used in the FlexX
software were obtained from The Protein Data Bank (code: 1DXO). A molecular
visualization system called PyMOL was used to prepare the docking frames. Construction of
six different receptors was done with the FlexX software by selecting the active site
containing amino acids from monomer A and C of the enzyme crystal structure. Two water
molecules were present in each of the receptors. Receptor 1 includes FAD (as it is in the Xray coordinates) as a cofactor with duroquinone as the reference ligand (X-ray coordinates
edited by FlexX for correct atom hybridization and bond type), and the binding site is
defined within an interface of 6 Å encompassing the reference ligand. Receptor 2 includes
FADH2 (FAD X-ray coordinates modified) as a cofactor with duroquinone as the reference
ligand (X-ray coordinates edited by FlexX for correct atom hybridization and bond type) and
the binding site is defined within an interface of 6 Å encompassing the reference ligand.
Receptor 3 is the same as Receptor 1 but has an interface radius of 8 Å. Receptor 4 is the
same as Receptor 2 but has an interface radius of 8 Å. Receptor 5 includes FAD as a
cofactor with the active site defined by a sphere of 8.5 Å with N5 from FAD as its center.
Receptor 6 includes FADH2 as a cofactor with the active site defined by a sphere of 8.5 Å
with N5 from FADH2 as its center.

$watermark-text

In FlexX flexible docking calculations, the initial position of the substrate is outside the
active site. Then, an algorithm for fragmenting the quinone substrate is executed, and a base
fragment is automatically selected and placed in the active site on which an incremental
construction algorithm is performed. From these calculations, each substrate examined using
different receptors has a set of solutions where the closest poses (based on score, position
and interactions with the protein) were selected for detailed investigation. On these selected
poses, the influence of the cofactor state (oxidized - FAD, or reduced - FADH2 form),
receptor radius, and the inclusion/lack of inclusion of a reference ligand was studied. In
addition, the total score was used as an estimate of the free energy of binding and was
subsequently used in a plot of theoretical free energies of binding versus experimental free
energies of binding.75

$watermark-text

The docking method is based on the experimental observed range of nonbonded contact
geometries revealed by statistical analysis of the Cambridge Structural Database (CSD); the
analysis of the CSD is used to define the range of allowed angles and dihedrals describing
the nonbonded contact geometry.82 The program discards any solution with electrostatic
repulsion (based on a threshold limit distance). The scoring function accounts for hydrogen
bonds, ionic interactions, hydrophobic contact surface, and the number of rotatable bonds in
the substrate; it is a modification of Böhm’s function.78–80 The limitations of the scoring
function are that it does not account for differences in binding strengths between various
neutral hydrogen bonds or ionic interactions, and it does not include the conformational
energy of the substrate.75, 82 The FlexX algorithm breaks down the substrate into fragments
where one is automatically elected as the base fragment,78 and then the fragments are
connected flexibly during docking in an incremental way.77 In the triangle algorithm,
triangles of interaction centers are formed using the base fragment, and those are mapped
onto triangle points lying on the receptor’s surface. As an alternative to the triangle
algorithm, a line algorithm is used when only two interactions exist simultaneously between
the substrate and the enzyme. The receptor is rigid and the ligand is flexible for both
algorithms.
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Voltammetry

$watermark-text

Cyclic voltammetry (CV) experiments were performed with a computer-controlled EG&G
PAR model 273A potentiostat and a three-electrode setup that included a (pretreated) glassy
carbon working electrode (A = 0.07 cm2, CH Instruments, Austin, TX), a homemade 99.9%
platinum counter electrode (d = 0.05 cm), and Ag/AgCl (3.0 M KCl, CH Instruments)
reference electrode. The working electrode was polished, prior to its electrochemical
pretreatment, on a Buehler microcloth with 1 micron Alpha alumina slurry micropolish.
Pretreatment of the working electrode was achieved by applying +1.5 V for 10 min, a
method that essentially serves to eliminate any electrochemically-active species on the
surface of the electrode that may interfere with data collection. Scans were conducted at a
rate of 0.1 V s−1 at room temperature in 0.1 M phosphate buffer/0.1 M KCl solution at pH
7.10.

RESULTS AND DISCUSSION
Kinetic Studies on Triggerable Quinones

$watermark-text

It is known that NQO1 from various mammalian species can reduce—albeit with greatly
varying rates—a broad range of small- and large-sized quinone substrates, ranging from the
simple 1,4-benzoquinone to the very complex geldanamycin quinone.83 This apparent
“universal” ability to catalyze the reduction of such different-sized quinones has been
attributed to the quite large quinone/nicotinamide binding site in human and mouse NQO1
(360 Å3).33 However, to the best of our knowledge, there are no studies that quantitatively
address the effects of systematic variations in quinone ring substituent size on human NQO1
Vmax and Km values under similar experimental conditions. Having in hand these readily
comparable kinetic parameters is crucial to gaining a more thorough understanding of the
reactivity of different hNQO1 substrates, particularly those that can be used in the delivery
of drugs via prodrug or triggered-release methodologies.

$watermark-text

Presented in Table 1 are the recombinant human NQO1 kinetic parameters (Km, Vmax, kcat,
and kcat/Km), two-electron aqueous reduction potentials (E1/2) and van der Waals volume
for the family of quinone propionic acid (QPA) derivatives studied here. For comparison
purposes, the collection of QPA derivatives is subdivided into four groups: a) quinone
propionic acids having different substituents at the R1 position of the quinone ring for the
trimethyl lock series (R3=R4=CH3), b) a charged and neutral version of a quinone propionic
acid having the trimethyl lock (R1=R2=R3=R4=CH3), c) trimethyl-locked quinone propionic
acids with substituent variations at R1 and R2, and d) quinone propionic acids that do not
possess the trimethyl lock motif.
Substituent Variation at the R1 position on the Quinone Ring of the Trimethyl Lock Series
We obtained the kinetic parameters for the rhNQO1-catalyzed reduction of four trimethyllocked quinone propionic acids (R2–R4= CH3) that differ in their functional group at the R1
position on the quinone ring (R1 = Br, H, CH3, CH3O). We selected the R1 position for
substituent variation due to its minimal influence on the geometry of the trimethyl lock
“side” of the quinone ring that dictates the rate of cyclization of the hydroquinone resulting
from reduction.32, 69 Upon initial perusal of the data in Table 1, there is no apparent welldefined relationship between Vmax, kcat, or kcat/Km and the two-electron quinone reduction
potential E1/2, an interesting outcome and one that indicates steric effects play a dominant
role in the enzyme-catalyzed, two-electron reduction of these quinones; we elaborate on
these observations later.
It is noteworthy that QBr-COOH (R1=Br) and QH-COOH (R1=H) are the best rhNQO1
substrates in this trimethyl lock series based on their Km, Vmax, kcat, and kcat/Km values. The
Biochemistry. Author manuscript; available in PMC 2013 October 09.
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rhNQO1 is able to reduce these two substrates quickly (about 45 molecules per second) and
efficiently (~106 M−1 s−1). The observed Michaelis constant of Km = 41 µM (QBr-COOH)
and Km = 50 µM (QH-COOH), as well as the maximum velocity values of Vmax = 88
µmol·min−1·mg−1 (QBr-COOH) and Vmax = 83 µmol·min−1·mg−1 (QH-COOH), were found
to be statistically indistinguishable at the 95% confidence level. However, the Km and Vmax
of QMe-COOH (158 µM, 38 µmol·min−1·mg−1) and QMeO-COOH (447 µM, 42
µmol·min−1·mg−1) are substantially different from each other and from those for the QBrCOOH and QH-COOH, with their higher Km values reflecting their lower rhNQO1 affinity.

$watermark-text
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The impact of substituent at the R1 position for the trimethyl-locked quinone propionic acids
(R2–R4= CH3) follows the general trend of the larger is the functionality at R1, the smaller is
the Vmax and binding capability (larger Km). When comparing the quinone propionic acids
(R2–R4= CH3) with increasing size of the substituent at R1 (H < CH3 < CH3O), the Km
increases, as expected for steric interactions between the quinone ring and the hNQO1
binding motif that result in an unfavorable alignment and position of the quinone ring in the
active site.35 Interestingly, Vmax decreases with increased size of R1 substituent on the
quinone propionic acid ring. This is quite evident when comparing the QH-COOH, QMeOCOOH, and QMe-COOH species, as the Vmax of the hydrogen variant (83 µmol·min−1·mg−1)
is roughly two times greater than that of the methyl-substituted quinone propionic acid (38
µmol·min−1·mg−1) and the methoxy derivative (42 µmol·min−1·mg−1). Steric hindrance has
previously been suggested as the cause of lower reduction rates for indolequinones and
benzoquinone mustard compounds.53, 56, 62 Although it could be argued that the differences
in Vmax observed here are due solely to differences in the electronic properties of the
quinone propionic acids, it is clear this is not the case. Such a conclusion is supported by our
observation that the methoxy derivative has a reduction potential (E1/2 = 0.098 V) very close
to that of QH-COOH (E1/2 = 0.117 V), but the Vmax of the methoxy derivative (42
µmol·min−1·mg−1) is roughly half that of QH-COOH (83 µmol·min−1·mg−1) and is almost
identical to that of QMe-COOH (38 µmol·min−1·mg−1) which has a much more negative E1/2
(0.047 V). Thus, steric factors appear to be dominant in the rhNQO1-catalyzed reduction of
these trimethyl-locked quinone propionic acids.
The Effect of Neutral versus Charged Trimethyl-locked Quinone Propionic Acid

$watermark-text

To investigate the rhNQO1-catalyzed reduction of a neutral quinone versus a negativelycharged quinone, we studied one trimethyl-locked quinone propionic acid
(R1=R2=R3=R4=CH3) derivatized with ethanolamine via an amide bond (QMe-ETA) that is
electrically neutral at the pH values used here;84 we compared its rhNQO1 kinetic values to
those obtained for QMe-COOH that is anionic at physiological pH due to its deprotonated
carboxylic acid group.47 QMe-ETA yields a significantly higher maximum reduction
velocity (60 µmol·min−1·mg−1) in comparison to the anionic QMe-COOH derivative (38
µmol·min−1·mg−1); however, the Michaelis constants are statistically indistinguishable. The
increase of 22 µmol·min−1·mg−1 in Vmax for the QMe-ETA is possibly due to the lack of
charge on this substrate, or the QMe-ETA may adopt a conformation in the active site of the
enzyme that promotes more favorable interactions. These hypotheses will be discussed later
in the sections addressing outcomes from molecular docking studies.
Substituent Variation at the R1 and R2 positions on the Quinone Ring of the Trimethyl Lock
Series—QdiMeO-COOH
Although this analog possesses the trimethyl-lock structural motif, QdiMeO-COOH does not
fall into the category discussed in the previous section, because it does not have a methyl
group at the R2 position of the quinone ring. But it was synthetically facile and possesses the
core portion of Coenzyme Q10, and thus it was added to our library of quinone propionic
acids for investigation. The Km value of the dimethoxy derivative is statistically
Biochemistry. Author manuscript; available in PMC 2013 October 09.

Mendoza et al.

Page 7

indistinguishable from that of the mono-methoxy quinone propionic acid. However, the
maximum reduction velocity for QdiMeO-COOH is only one-third that of the mono-methoxy
derivative, QMeO-COOH (Vmax = 42 µmol·min−1·mg−1). The significantly lower rhNQO1
reduction velocity most likely results from the exceptional amount of steric interactions
between the methoxy groups and the NQO1 binding site that arise from the presence of
adjacent methoxy groups in QdiMeO-COOH. It is known for ortho-dimethoxy-1,4benzoquinones that one of the methoxy groups lie out of the plane of the quinone ring.85, 86
Thus, the out-of-plane methoxy substituent of QdiMeO-COOH will provide for unfavorable
steric interactions with the NQO1 active site.

$watermark-text

The Presence versus the Absence of the Trimethyl-Lock Motif in the Quinone

$watermark-text

In order to probe the effect of trimethyl-lock motif presence/absence on the rhNQO1 kinetic
parameters, we examined two quinone propionic acids that do not possess the trimethyl lock.
The Q’-COOH derivative does not have a methyl substituent at R3, and QnogemMe-COOH
lacks methyl groups at the geminal R4 position. For Q’-COOH that possesses a hydrogen
(instead of a methyl) at the R3 position on the quinone ring, its observed Michaelis constant
is 20 µM, a value that reflects substantially tighter binding of Q’-COOH by rhNQO1 than
QMe-COOH (158 µM) which possesses the trimethyl-lock motif. In addition, QH-COOH and
Q’-COOH both have a hydrogen group on the quinone ring, but the difference in hydrogen
group position at R1 versus R3 makes QH-COOH a trimethyl-lock derivative and Q’-COOH
not; the presence of the trimethyl lock in QH-COOH leads to a ~21° deviation from planarity
of the quinone ring when compared to Q’-COOH.69 These two positional isomers have
significantly different Km values of 20 µM (Q’-COOH) and 50 µM (QH-COOH), most likely
because of the impact of ring distortion on binding of QH-COOH in the active site of
rhNQO1. To further probe the effect of the trimethyl-lock motif, we examined the quinone
propionic acid with no germinal methyl groups on the propionic side chain (R4 position),
QnogemMe-COOH, whose quinone ring is planar.69 It was found that QnogemMe-COOH was
even more specific toward the enzyme, as noted by its Km value of roughly 5 µM and Vmax
of 66 µmol·min−1·mg−1; in addition, its catalyzed reduction is quite efficient (6.8 × 106 M−1
s−1).
Possible Correlations Between hNQO1-catalyzed Kinetic Parameters and Quinone
Propionic Acid Characteristics

$watermark-text

Based on the widely accepted two-electron reduction (hydride-transfer) mechanism for the
NQO1-catalyzed reduction of various quinones,18 it is anticipated that there should exist a
relationship between the physical and chemical properties of the quinone substrates and the
kinetic observables associated with their reduction by hNQO1. From previous studies with
other mammalian (rat and mouse) NQO1, it has been suggested that the “reactivity” of
quinones toward murine NQO1 does not strictly depend on the two-electron reduction
potential87 or lipophilicity88 of the quinone substrates; others have noted qualitative trends
between rat NQO1 activity and the octanol-water partition coefficient,70 as well as van der
Waals volume,66 of certain quinones. Due to the differences in the structure of human
NQO1 and its capability to activate chemotherapeutic agents49, 63 and menadione (vitamin
K3)64, 65 versus that from murine sources, it is of great importance to learn what if any
quantitative relationships exist between human NQO1 reduction kinetic parameters for
analogous quinone substrates and the quinone substrate properties. To the best of our
knowledge, there are no studies that quantitatively address the effects of systematic
variations in quinone ring substituent size on human NQO1 reactivity.
Upon inspection of the reactions governing the mechanism for the ping-pong, bi-bi,
hNQO1-catalyzed reduction of quinones (Q) to hydroquinones (H2Q) using NADH as the
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hydride (electron) source, kcat and kcat/Km are predicted to have a dependency on the
characteristics of the quinone substrate:
Equation 1

Equation 2

$watermark-text

Equation 3

Equation 4

$watermark-text

In particular, kcat is a function of the first-order rate constants for hNQO1 reaction with
NADH (k2, Equation 2) and the quinone substrate (k4, Equation 4), with kcat = k2k4/(k2+k4);
while kcat/KmQuinone = k3k4/(k−3+k4), where k3 and k−3 are the forward and reverse rate
constants for quinone substrate binding with reduced hNQO1 (Equation 3). Under the
assumption of the first-order reaction of reduced hNQO1 with quinone (Equation 4) being
the rate-limiting step, kcat = k4 and kcat/KmQuinone = k3k4/k−3. It was found that there is no
apparent correlation between log kcat and quinone propionic acid two-electron reduction
potential E1/2 or log kcat and quinone propionic acid van der Waals volume89 (Figures S2–
S3). It is possible that for some of the substrates studied, the first-order reaction of reduced
hNQO1 with quinone (Equation 4) is not the rate-limiting step, leading to kcat = k2. In
addition, in the case of comparable reaction rates (k2 ≈ k4), kcat may depend on k2 and k4.
Both of these scenarios would lead to decreased correlation between log kcat and E1/2 or log
kcat and quinone propionic acid van der Waals volume. However, kcat/KmQuinone should not
be sensitive to these concerns of k2 versus k4.

$watermark-text

Interestingly, a plot of log(kcat/Km) vs. van der Waals volume, Figure 1, gives rise to two
identifiable relationships, yielding two sets of quinone propionic acids that we refer to as
fast (green points) or slow (red points) with respect to their reduction by rhNQO1. A similar
observation has previously been noted in the rat NQO1-catalyzed reduction of a wide variety
of quinone substrates, such as anthraquinones and naphthoquinones.66 In addition, the same
slow and fast quinone substrates are noted in a plot of log(kcat/Km) vs. E1/2, with the
increased size of the slow substrates yielding a negative correlation, Figure S4. This latter
observation is similar to what has been found in attempted correlations of glucose oxidase
activity with the reduction potentials of substituted ferrocenes, where it was found that
oxidase reactivity decreased with more favorable ferrocene reduction potential; this outcome
was attributed to steric interactions between the glucose oxidase and the substituted
ferrocenes.90 The relationships we observe for the two groups of quinone propionic acids in
Figure 1 are quite reasonable (R = 0.9008 for the fast substrates, green line; 0.96661 for the
slow quinones, red line), but this may be due to the small range of van der Waals volumes
studied here. In total, our observations clearly point to the significant role sterics plays in the
hNQO1-catalyzed NADH reduction of the quinone propionic acids. As a result, we
undertook computational substrate-enzyme docking studies in order to possibly develop a
more comprehensive relationship between the observed kinetic parameters and information
about quinone substrate interactions with rhNQO1.
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Docking Studies on Triggerable Quinones

$watermark-text

To elucidate the possible influence of all the factors associated with the computed
interactions between the quinone propionic acids (QPAs) and hNQO1, a variety of receptors
were defined and evaluated as outlined below. In docking, the way in which a receptor is
defined affects in different ways the predictions of substrate interactions. Specifically, it is
important to know what amino acids are to be included as defined by the radius of
interaction (“interface radius”). Also, for the case at hand, the cofactor oxidation state (FAD
vs. FADH2) of the receptor must be selected. The docking methods employing the selected
receptors were validated using a known hNQO1-substrate crystal structure. Then, all the
QPAs evaluated in the kinetic assays were docked in the active site of hNQO1 using the
defined receptors. In addition, the QPA amine derivatives, QN-Me-COOH and Qn-pr-NHCOOH, were also docked in the active site of hNQO1with the aim of predicting their
position and binding energy because of the lack of enzyme kinetic data for them.
Which hNQO1 environment should be used for validation of the docking methods?

$watermark-text

For method validation purposes, we examined docking outcomes for a quinone whose
interactions with hNQO1 are well known from an X-ray crystal structure of the quinone
bound in the active site of hNQO1.33 We selected duroquinone (2,3,5,6-tetramethyl-1,4benzoquinone) due to its structural similarity to the core of the quinone propionic acids
studied here. For docking of duroquinone with all of the receptors described below, it was
found that excellent results could be achieved, with an observed root-mean-square deviation
(RMSD) < 0.5 Å for the best prediction and an RMSD < 1.34 Å for the poorest one. In all of
these docking outcomes, it was found that the orientation of the duroquinone ring was very
similar, with differences of less than 1.2 kJ·mol−1 being observed between the lowest energy
versus 20th-lowest energy outcome for each receptor. In Figure 2 is shown the best pose
(RMSD = 0.45 Å) for duroquinone (pink) in comparison to its position in the original crystal
structure (yellow).
FAD (oxidized) versus. FADH2 (reduced)

$watermark-text

In the NQO1-catalyzed reduction of quinones by NADH, there is still much debate as to
where the negative charge resides after the first hydride transfer occurs (flavin reduction by
NADH). The most prominent proposal in the literature is that in which the negative charge
is delocalized in the region of the N(1)-C=O(2) portion of the flavin, with it being stabilized
through hydrogen bonding interactions with the phenol functionality of Tyr-155. During
NAD+ displacement, it is thought that the O(2) of the flavin is protonated to form
FADH2.34, 40, 91, 92 Subsequent reduction of the quinone occurs via a mechanism that is
effectively the reverse of that for formation of FADH2. These unproven mechanistic
processes are outlined in Scheme 2.40, 93 There are also concerns about the geometry of
FAD versus FADH2 and how protonation can affect its conformation. In the literature, it has
been reported that the shape of FADH2 in solution is butterfly-like (versus planar for FAD),
but in most modeling studies, FADH2 is modeled as being planar in the active site.33, 91
The outcome solutions from docking the quinone propionic acid analogs into the different
receptors having an active site possessing FAD or FADH2 as cofactor were examined. For
this, we compared the results from receptor 1 versus receptor 2, receptor 3 versus receptor 4,
and receptor 5 versus receptor 6. In all cases, the positions of the quinones were effectively
the same. For the poorest score in each case, a slight increase of 0.6 kJ·mol−1 was observed
for the receptor containing FAD versus the receptor containing FADH2; for the best score,
the increase was 0.8 kJ·mol−1.
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Interface Radius of 6 Å vs. Interface Radius of 8 Å
The binding conformations of the quinone analogs were examined for the case wherein the
only difference was the interface radius of the active site. We compared receptor 1 to
receptor 3, and receptor 2 to receptor 4. For the two interface radii, the orientation of the
quinone analogs in all the receptors mentioned above were the same, and the outcome
solution with the lowest score energy for the duroquinone in each receptor differed by only 1
kJ·mol−1.
Defining the Active Site (Reference Ligand versus Sphere)

$watermark-text
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The binding conformations of the quinone propionic acids were examined by defining the
active site differently. In the case of receptors 3 and 4, the ligand bound to the enzyme was
used as reference ligand (duroquinone), and it had an interface radius of 8 Å defined from its
position. In the case of receptor 5 and 6, the nitrogen N5 of the FAD or FADH2 cofactor was
used as the sphere center, and an interface radius of 8.5 Å was defined from it. We
compared receptor 3 versus receptor 5, and receptor 4 versus receptor 6. In these scenarios,
the outcomes with the lowest score and the best prediction differ in their orientations only
for duroquinone but not for the other quinone analogs. However, the outcome for the lowest
energy value and the one associated with the best orientation is different for all of the
quinones. The lower energy score is smaller by 1 kJ·mol−1 in the receptors possessing the
active site defined by the 8.5 Å radius sphere. The best prediction corresponds to the
quinone located deeper in receptors 5 and 6. In this case, the energy is 0.6 kJ·mol−1 lower
than in receptors 3 and 4. We conclude in this case for the quinone propionic acids, even
though there is a difference in score energy, this difference is minimal and does not affect
the outcome. Therefore, there is no apparent influence of the chosen active site definitions
on quinone positions or score energies.
After comparing all the receptors, we observed that there is no significant effect of cofactor
oxidation state or interface radius, on the docking outcomes. In addition, the definition of the
active site has little influence on the docking solutions. In Figures S5 and S6 are represented
the lower score frame of QBr-COOH (shown as a representative example of the outcomes
observed for all of the quinone propionic acid homologs) in each receptor and the
corresponding poseview, so as to help to visually support the conclusions made above.
These conclusions are also based on data in Table S1 that contains the lowest score energies
for QBr-COOH in all the receptors.
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Outcomes from Docking Studies for the Quinone Propionic Acids
The solutions using receptor 1 were utilized in comparisons of the quinone propionic acids,
and those outcomes are an accurate representation of what is observed in all the receptors as
visualized in Figure 3 and their superimposed images for the trimethyl-lock motif (Figure
S7), quinones with the trimethyl-lock motif present and absent (Figure S8), and quinones
differing in their charge (Figure S9). For the trimethyl-lock series, it was found that QBrCOOH penetrates most deeply into the active site of hNQO1, whereas QMeO-COOH
penetrates the least. In addition, QBr-COOH, QH-COOH and QMe-COOH all lay parallel to
the isoalloxazine ring of the FAD cofactor, but the distance between the sites of the quinone
ring for possible hydride transfer and the flavin is different due to slight variations in
quinone ring orientation with respect to the flavin, vide infra. The methoxy-, dimethoxy-,
and amine-substituted quinone derivatives do not bind as tightly as the other quinone
analogs. The QPAs lacking the trimethyl-lock motif penetrate into the active site most
deeply, with Q’-COOH being closest to the flavin isoalloxazine ring. Interestingly, the
neutral QMe-ETA is located deeper in the active site of the enzyme than is the anionic QMeCOOH. Using the criteria of quinone orientation with respect to and distance from the flavin
of hNQO1, all of the observations from docking studies are in qualitative agreement with the
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kcat/Km values. The obvious possible explanation for the differences in quinone propionic
acid orientation and distance from the flavin is that of steric interactions resulting from the
presence of more bulky substituents on the quinone ring or changes in quinone ring planarity
due to the presence of the trimethyl lock.69 Other research groups have reported that a bulky
amine at the 2-position of the quinone ring of indolequinones and quinolinequinones result
in a tremendous decrease in their rate of hNQO1-catalyzed reduction, thereby making them
poor substrates.51, 52, 54
Quantitative Relationships Between Docking Outcomes and NQO1-catalyzed QPA
Reduction Parameters

$watermark-text

We investigated a possible correlation between the theoretical binding energies from the
docking outcomes75 and those derived from the experimentally determined Km values.
Unfortunately, there was no relationship between these experimental and theoretical
energies, as noted in Figure S10. However, this is not necessarily surprising, based on the
controversy that exists in the literature about whether or not binding energies from docking
studies can be correlated with experimental reactivities.38, 59–61, 94

$watermark-text

Based on our observations in Figure 1 that indicate QPA substrate specificity or catalytic
efficiency (kcat/Km) is strongly influenced by the size of the QPA, we posited that the
second-order rate constant is a function of the distance of substrate approach to the reduced
flavin site in hNQO1. Thus, we explored the possible application of Marcus-like95 theories
regarding hydride-transfer (H tunneling) in enzyme systems. A basic tenet of these theories
is the rate constant for hydride-transfer between a donor and an acceptor is exponentially
dependent on the distance of separation between the hydride donor and acceptor atoms when
the system is in the tunneling ready state.96 This adaptation of Marcus theory to describe the
rate of hydride transfer is achieved by inclusion of a Franck-Condon term that relates the
efficiency of tunneling through a barrier to the donor-acceptor distance (DAD) and the mass
of the tunneling species. Thus, we examined docking outcomes and measured the hydride
donor-acceptor distance for each of the quinone propionic acids as a function of the possible
paths in Scheme 2.

$watermark-text

The values of the distance from N5 of the flavin center in hNQO1 to the possible hydride
transfer site of the quinones,40, 93, 97 denoted here as the hydride donor-acceptor distance
(DAD), are presented in Table 2 for the best score energy obtained for each quinone
propionic acid substrate. We assumed that all paths in Scheme 2 are possible. Upon
examining possible relationships between the substrate specificity or catalytic efficiency
(kcat/Km) and the DAD for the three paths in Scheme 2, we found that there exists a an
acceptable correlation between the log(kcat/Km) and DAD for the scenario wherein the
hydride is transferred from the N5 of the flavin of NQO1 to the carbon ortho to the carbonyl
(Path A in Scheme 2, CA) of the QPAs; this is reflected by the R value of 0.9447 for this
plot in Figure 4 for the set of eight different quinone propionic acids studied here and is
most likely due to the similar structural characteristics of the hNQO1 substrates. No
apparent correlation exists between the log(kcat/Km) and DAD for either Path B (hydride
transfer to the carbonyl carbon, CB) or Path C (transfer to the carbonyl oxygen, OC), Figures
S11 (R = 0.4841) and S12 (R = 0.2534). Although the outcomes are preliminary in nature in
regard to evaluating application of this data treatment route, the suggested 1,4 addition of
hydride from the correlation in Figure 4 makes sense from an energetics point of view.59, 93
Due to the goodness of the correlation for the log(kcat/Km)-DAD relationship above, we
calculated the predicted value of kcat/Km for Q(Me-N)-COOH and Q(n-pr-NH)-COOH, two
substrates whose kinetic parameters cannot be obtained due to their spectral overlap at 340
nm with the NADH that is used to obtain the rates of reaction. This was achieved using the
best fit equation from Figure 4 of log(kcat/Km) = 14.668±0.405 − 2.601±0.118*DAD. The
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kcat/Km value for Q(n-pr-NH)-COOH was calculated to be 1.2 × 105 M−1 s−1 and that for
Q(Me-N)-COOH is 2.5 × 104 M−1 s−1, with the former being comparable to that of QMeCOOH and the latter similar to the kcat/Km value for QdiMeO-COOH. These values clearly
place the amino-substituted quinone propionic acids in the slow set of hNQO1 substrates, as
one might expect based in the steric bulk of the amine substituent.

$watermark-text

We are unaware of any published reports that have investigated application of Marcus-like
theory to reactivities of NQO1-catalyzed NADH reduction of quinones and the distance
from N5 of the flavin center in hNQO1 to the possible hydride transfer site of the quinone
substrates. Our initial positive outcomes with this model using a family of quinone propionic
acids opens up opportunities of exploration with other classes of quinones, as well as
investigations of NQO1 structural changes. For example, studies are necessary to elucidate
the impact of NQO1 mutations on the rate of substrate reduction, wherein positioning of the
flavin in the enzyme, and with respect to the bound substrate, can be tailored through sitedirected mutagenesis of amino acids behind the flavin site.64 In addition, investigations are
warranted regarding the influence of protein motion (reorganization energy)95 on the rate of
hydride transfer to substrates; this can be probed via kinetic isotope effect experiments and
those using the apo enzyme reconstituted with flavins having different E1/2 values.98

$watermark-text
$watermark-text

In summary, through the use of a 96-well microplate enzyme assay, we have been able to
obtain highly reproducible kinetic parameters for the human recombinant NQO1-catalyzed
NADH reduction of quinone propionic acids, including those that can be used as a trigger
group for drug delivery systems.32 As a result, we were able to observe significant
differences in enzymatic activity resulting from minor structural changes to the quinone ring
and the propionic acid side chain of the rhNQO1 substrates. The differences in reactivity for
the quinone propionic acids are proposed to be the result of variations in enzyme-substrate
steric interactions, an observation similar in nature for benzoquinone mustards.53, 56
Outcomes from molecular docking studies qualitatively confirm this hypothesis, as the more
active quinone propionic acids are found to penetrate deeper into the flavin active site of the
rhNQO1. A very strong correlation is found between log(kcat/Km) and molecular-dockingderived hydride donor-acceptor distance, DAD, for the case of hydride transfer from the N5
of the flavin of NQO1 to the carbon ortho to the carbonyl (Path A in Scheme 2, CA), in
agreement with Marcus-like theories concerning enzymatically facilitated hydride transfer
reactions. Overall, our observations enrich the knowledge base for simple quinone-hNQO1
interactions, and provide valuable information for the design of enzyme triggerable systems.
For example, the docking and kinetics studies reveal that the presence of a longer side chain
attached to the quinone (i.e. QMe-ETA versus QMe-COOH) can lead to the quinone core
being able to penetrate deeper into the active site of rhNQO1; this suggests that addition of
spacers to the quinone derivatives99 may facilitate quinone-enzyme binding and perhaps
their rate of enzymatic conversion.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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rhNQO1

recombinant human NAD(P)H:quinone oxidoreductase type 1

QBr-COOH

3-(5-bromo-2,4-dimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)-3methylbutanoic acid

QH-COOH

3-(2,4-dimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)-3methylbutanoic acid

QMe-COOH

3-methyl-3-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1yl)butanoic acid

QMeO-COOH

3-(5-methoxy-2,4-dimethyl-3,6 dioxocyclohexa-1,4-dien-1-yl)-3methylbutanoic acid

Q’-COOH

3-(4,5-dimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)-3methylbutanoic acid

QnogemMe-COOH

3-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)propanoic acid

QdiMeO-COOH

3-(4,5-dimethoxy-2-methyl-3,6-dioxocyclohexa-1,4-dien-1-yl)-3methylbutanoic acid

QMe-ETA

N-(2-hydroxyethyl)-3-methyl-3-(2,4,5-trimethyl-3,6dioxocyclohexa-1,4-dien-1-yl)butanamide

Q(Me-N)-COOH

3-(2,4-dimethyl-5-(methylamino)-3,6-dioxocyclohexa-1,4-dien-1yl)-3-methylbutanoic acid

Q(n-pr-NH)-COOH

3-(2,4-dimethyl-3,6-dioxo-5-(propylamino)cyclohexa-1,4-dien-1yl)-3-methylbutanoic acid

QPA

quinone propionic acid
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Figure 1. Relationship between substrate specificity and quinone propionic acid van der Waals
volume for fast (green points/line) and slow (red points/line) substrates

Lines are the best fit to the data points as obtained by linear least-squares analysis. Error
bars represent one standard deviation (n = 3). The van der Waals volumes were calculated
according to the literature.89
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Figure 2. Best prediction for docked duroquinone in receptor 1 compared with the position of
the duroquinone in the original crystal structure

$watermark-text

The position of the docked duroquinone (pink) differs from the original duroquinone
(yellow) as noted by the 0.45 Å root-mean-square deviation (RMSD). Representation of
amino acids (stick display; color by atom type, carbon atoms colored in purple) and FAD
(sticks display; color by atom type, carbon atoms colored in cyan) in receptor 1.
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Figure 3. Structural frames of FlexX-docked quinone propionic acids in the active site of hNQO1

Stick display style in all the frames, FAD (color by atom type; carbon atoms colored in
cyan), amino acids (color by atom type, carbon atoms colored in purple) and dockedquinones (color by atom type, carbon atoms in pink).
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Figure 4. Correlation between quinone propionic acid specificity and FAD N5-quinone acceptor
site (CA) distance

R = 0.9447 for the best linear-least-squares fit (green line). Error bars represent one standard
deviation (n = 3).
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Scheme 1.

Reduction and cyclization of quinone propionic acid (QPA) trigger groups.

$watermark-text
$watermark-text
Biochemistry. Author manuscript; available in PMC 2013 October 09.

Mendoza et al.

Page 24

$watermark-text
$watermark-text
$watermark-text
Scheme 2.

Hydride transfer mechanism for possible atom sites of QPAs.
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Quinone

50±11

447±102

158±41

42±5

38±5

41±8

88±7

83±8

Km
(µM)

Vmax
(µmol·min−1·mg−1)
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20.±3

22±3

43±4

45±4

kcat
(s−1)

0.117±0.002

0.098±0.001

0.047±0.002

4.8±1.2 × 104

1.2±0.4 × 105

0.095±0.001

1.1±0.2 × 106

8.5±2.0 × 105

E1/2 vs.
SHE
(V)

kcat/Km
(M−1·s−1)

249

258

232

251

van der Waals
volume
(Å3)

Values reported are the mean ± one standard deviation for three independent determinations. [NADH] = 1.00 × 10−4 M in all cases. The van der Waals
volumes were calculated according to the literature.89
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Kinetic parameters for the reduction of quinone propionic acid derivatives by hNQO1
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376±87

20±3

5±1

78±3

66±4

132±32

60±7

14±1

Km
(µM)
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Vmax
(µmol·min−1·mg−1)

34±2

40.±2

7.2±0.5

31±4

kcat
(s−1)

0.128±0.001

0.144±0.001

0.143±0.002

2.0±0.3 × 106

6.8±1.4 × 106

0.041±0.001

2.3±0.6 × 105

1.9±0.5 × 104

E1/2 vs.
SHE
(V)

kcat/Km
(M−1·s−1)

215

232

282

295

van der Waals
volume
(Å3)

$watermark-text

$watermark-text
Quinone

Mendoza et al.
Page 26

Biochemistry. Author manuscript; available in PMC 2013 October 09.

Mendoza et al.

Page 27

Table 2
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Energy scores and hydride donor-acceptor distances (DAD, distance from N5 of flavin to
the possible hydride transfer atoms) for the quinone propionic acids
Donor-Acceptor Distance
(Å)
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Quinone

Score (kJ·mol−1)

[N5-CA]

[N5-CB=O]

[N5-OC]

QBr-COOH

−25.2

3.25

3.47

3.58

QH-COOH

−24.0

3.40

4.11

4.50

QMe-COOH

−26.4

3.58

3.54

3.71

QMeO-COOH

−20.3

3.83

3.90

3.50

QdiMeO-COOH

−28.4

4.05

4.05

3.68

Q’-COOH

−27.0

3.18

3.81

3.92

QnogemMe-COOH

−25.8

3.22

3.49

3.68

QMe-ETA

−28.5

3.43

3.73

3.81

Q(Me-N)-COOH

−24.8

3.95

3.90

3.45

Q(n-pr-NH)-COOH

−21.0

3.68

4.36

4.32
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